Philip Morris (PM) Offering Possible 9.65% Return Over the Next 30 Calendar Days

Philip Morris's most recent trend suggests a bearish bias. One trading opportunity on Philip Morris is a Bear Call Spread using a strike $72.50 short call and a strike $77.50 long call offers a potential 9.65% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $72.50 by expiration. The full premium credit of $0.44 would be kept by the premium seller. The risk of $4.56 would be incurred if the stock rose above the $77.50 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Philip Morris is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Philip Morris is bearish.

The RSI indicator is below 20 which suggests that the stock is in oversold territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Philip Morris

Philip Morris, Altria Are Facing ITC Investigations; What Should Investors Know?
Mon, 18 May 2020 16:45:00 +0000
The U.S. International Trade Commission has announced a probe into Altria and Philip Morris for alleged patent violations over iQOS heat-not-burn technology.

Ray Dalio Picks Up These 3 “Strong Buy” Stocks
Mon, 18 May 2020 13:30:31 +0000
COVID-19's impact has been crippling, but something positive may come from the pandemic. Billionaire Ray Dalio said in a live LinkedIn interview that in terms of the broader historical context, the recent economic downturn should be “relatively brief," and could spur significant societal progress. This would include a worldwide “restructuring” lasting approximately three to five years.“I know that’s a long time, but it’s not forever. The human capacity to adapt and invent and come out of this is much greater,” Dalio commented. He added, “I think we should be very excited about the new future. We’re now in a wonderful revolution in terms of the capacity to think and use that in a way. I would say that is absolutely the most treasured thing in the future.”Still making sure to account for the unknowns, Dalio has been diversifying his investments across geographic locations, asset class and currencies throughout the ongoing public health crisis. Looking to Dalio for investing inspiration, we used TipRanks’ database to find out if three stocks the billionaire recently added to the fund represent compelling plays. According to the platform, the analyst community believes they do, with all of the picks earning “Strong Buy” consensus ratings. Let’s jump right in.Philip Morris International (PM)Cigarette and tobacco manufacturing company Philip Morris has become known as a “sin stock." However, regardless of its product portfolio, Dalio sees plenty of upside in store.Recently, the billionaire’s fund acquired a new position in PM, snapping up 67,447 shares. The value of this new addition? More than $4.9 million.Turning now to the analysts, the stock boasts a strong fan base, which includes Piper Sandler’s Michael Lavery. He doesn’t dispute the fact that there are some headwinds facing the company. “PM expects near-term iQOS new user acquisition to be about 50% lower than it originally planned due to social distancing measures that have shut iQOS stores and made it harder to engage with consumers,” Lavery stated.That being said, the company has already surpassed Lavery’s expectations, which were cut to near-zero. The analyst even says that if PM can maintain the pace of its customer acquisition, there could be upside to his estimates. The analyst added, “We expect HeatStick volume growth of 20% in 2020E (1Q20: +45%) and believe 90-100 billion sticks in 2021 is still achievable.”While lower duty-free volumes and down-trading in Indonesia could take a toll on second quarter EPS, Lavery remains optimistic. “We remain bullish on PM's strong long-term outlook, and we expect nicotine demand to remain resilient near-term (particularly in times of personal stress),” he explained.It should also be noted that PM has had to grapple with patent infringement claims from British American Tobacco (BAT) and a transactional currency hit. Speaking to the first issue, Lavery said, “We reviewed BAT's six patents named in its U.S. complaint, and it is difficult to handicap an outcome, but a third-party reviewer of patents generally did not give BAT's relevant ones here very high marks.”As for the latter, Lavery points out that about $100 million of the currency hit in the first quarter of 2020 was driven by the revaluation of euro or dollar denominated payables in markets like Russia, but he doesn’t foresee another event of this magnitude happening again.Based on all of the above, Lavery kept an Overweight rating on the stock. He did reduce the price target from $98 to $95, but this still implies shares could climb 40% higher in the next year. (To watch Lavery’s track record, click here) Judging by the consensus breakdown, other analysts are in agreement. 7 Buys and 2 Holds add up to a Strong Buy consensus rating. In addition, the $83.56 average price target brings the upside potential to 23%. (See Philip Morris stock analysis on TipRanks)UnitedHealth Group (UNH)Hoping to help people live healthier lives and make the healthcare system work more efficiently, UnitedHealth Group offers a wide range of healthcare products and insurance services. While the late-March acceleration of the COVID-19 pandemic resulted in a somewhat lackluster quarter, Dalio believes the company’s future is bright.To this end, Bridgewater went in on UNH. In a purchase valued at $5,481,000, Dalio’s hedge fund scooped up 21,977 shares.Five-star analyst Michael Wiederhorn agrees that UNH is moving on to bigger and better things, noting that its Q1 performance was relatively solid. “Overall, UNH produced strong results and seems well-positioned to navigate the COVID pandemic due to a relatively stable top-line, a diversified business mix and a dominant position across its businesses.”Wiederhorn tells investors that management thinks the slowdown in non-COVID-irelated utilization, which was driven by highly constrained elective care and will be offset by the late-year pent-up utilization, will have a significant impact on MCR in the second quarter. As a result, despite some uncertainty surrounding COVID-19's impact, UNH maintained its full year 2020 EPS guidance of $16.25-$16.55.Adding to the good news, Wiederhorn argues that its Optum segment has a strong standing within the market. Expounding on this, he noted, “Trends at Optum remained solid, and management did note that even OptumHealth should be positioned to hold up relatively well due to its reliance on risk-based contracts, accounting for two thirds of revenues. Both OptumRx and OptumInsight have strong pipelines (though the timing of meetings was disrupted) with the latter of particular interest as companies look to improve the economics and delivery of healthcare.”Even though commercial enrollment could be hampered by elevated levels of unemployment, higher Medicaid should partially offset this. Additionally, UNH is in the early stages of pricing and benefit design for 2021, with its plans possibly including pricing for COVID-19 testing and a potential vaccine.Bearing this in mind, Wiederhorn maintained an Outperform call and $343 price target. Should this target be met, a twelve-month gain of 18% could be in the cards. (To watch Wiederhorn’s track record, click here)Turning now to the rest of the Street, other analysts also like what they’re seeing. With 12 Buys and 2 Holds, the word on the Street is that UNH is a Strong Buy. At $326.23, the average price target indicates 12% upside potential. (See UnitedHealth stock analysis on TipRanks)Accenture PLC (ACN)Dalio’s third recent addition, Accenture, provides management and technology consulting services and solutions to help its clients, which inhabit almost every industry, create lasting value. With the company relying on a new strategy, Dalio thinks it has set itself up for success.Not wanting to miss out on a compelling opportunity, Bridgewater pulled the trigger on 27,763 shares, giving it a new position in ACN. Looking at the value of the new holding, it comes in at more than $4.5 million.When it comes to the analysts, they are also singing the company’s praises. Writing for BNP Paribas, analyst Ben Castillo-Bernaus argues that COVID-19's disruption has presented investors with an opportunity to buy a “high-quality” IT service company, with ACN trading well below historical five-year average EBIT multiples.“Accenture remains ‘best in class’ and the recent weakness is an opportunity to gain a position in this IT Services global leader delivering 40% returns on capital,” Castillo-Bernaus stated. He added, “Accenture has been a pioneer in developing ‘the New’ with 65% of revenues now coming from high growth Digital, Cloud and Security services.”As for what makes the company so successful and allows it to continuously take market share, Castillo-Bernaus points to its investments in new technologies and growth areas. To back up this conclusion, the analyst cites its EUR1 billion investment in training each year and EUR800 million investment in R&D all while delivering margin improvements every year. On top of this, ACN conducts smaller-scale M&A, with it working alongside the companies before an acquisition to limit any potential deal failures.Castillo-Bernaus also noted, “We believe Accenture has customers that spend more than $100 million annually, with 98% of Accenture’s top 100 clients having been clients for more than five years. These ‘sticky’ relationships help Accenture maintain high margins and high returns as Accenture has a high number of ‘sole source’ wins where it does not even see competition in RFPs.”That being said, the company has started using a new approach. It will now organize itself by Strategy & Consulting, Interactive, Technology and Operations instead of by verticals, and the results will be reported geographically for these segments. “We believe it is too early to tell what kind of impact these changes will have, but Accenture has a positive track record of occasionally tweaking its growth strategy in order to best deliver on the opportunities ahead,” Castillo-Bernaus commented.It should come as no surprise, then, that Castillo-Bernaus joined the bulls. Along with an Outperform rating, he initiated coverage by setting a $215 price target. This target conveys the analyst’s confidence in ACN's ability to surge 17% in the next twelve months.In general, other Wall Street analysts have also been impressed. ACN’s Strong Buy consensus rating breaks down into 13 Buys and 2 Holds assigned in the last three months. However, the $195.29 average price target suggests modest upside potential of 6%. (See Accenture stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

7 Sin Stocks To Buy During The Coronavirus Shutdown
Sun, 17 May 2020 17:00:21 +0000
There's no question Americans are facing unprecedented stresses these days. Data suggests some Americans are relying on vices such as alcohol, tobacco and cannabis to get through the health crisis. At the same time, gamblers have been driven online for the time being due to casino closures.When times are good, people like to celebrate with a drink or a smoke or a roll of the dice. When times are hard, they turn to these activities as a distraction or a means of self-medication. Regardless of how you feel about the activities themselves, here are seven "sin stocks" to buy that Morningstar analysts say have significant upside.Philip Morris International Inc. (NYSE: PM)Philip Morris is one of the largest global tobacco companies and holds nearly a 30% market share of the international cigarette and heated tobacco markets.Analyst Philip Gorham says Marlboro customer loyalty is extremely high and Philip Morris has considerable pricing power. The company has a first-mover advantage in heated tobacco, but it remains to be seen whether or not heated tobacco can completely offset lost cigarette volumes over time. Gorham says a successful launch of iQOS in the U.S. would generate completely incremental revenue given the company currently has no U.S. products.Philip Morris shares also pay a sizable 6.9% dividend.Morningstar has a Buy rating and $98 price target for PM stock.See Also: 7 Best Cheap Stocks To Buy Or Sell Cronos Group Inc (NASDAQ: CRON)Cronos is one of the "big four" Canadian legal producers of cannabis and owner of brands such as PEACE NATURALS, COVE and Lord Jones. Cronos reported impressive 180% revenue growth in the first quarter, but it also reported a $45 million operating loss.Analyst Kristoffer Inton says write-downs associated with lower prices due to oversupply in the Canadian market were the cause of the loss. However, Inton says Cronos' write-downs are shrinking, whereas other cannabis producers' losses are growing. Morningstar is projecting Canadian cannabis demand will grow 20% annually over the next decade, and Cronos has the balance sheet to expand its market share.Morningstar has a Buy rating and $8.50 fair value estimate for CRON stock.Las Vegas Sands Corp. (NYSE: LVS)Las Vegas Sands is an international casino operator that owns casino resorts and hotels in Las Vegas, Macau and Singapore. Analyst Dan Wasiolek says Macau and Singapore are the keys to the bull case for Las Vegas Sands.Macau accounted for about 59% of Sands' earnings in 2019, and Singapore was another 31%. Wasiolek says Sand's has a dominant position in the high-growth Cotai Strip in Macau, and it has a duopoly in place in Singapore through at least 2030. COVID-19 shutdowns in Las Vegas and a 97% drop in gross gaming revenue due to COVID-19 may be scary, but Wasiolek estimates Las Vegas sands has 18 months of liquidity at nearly zero revenue.Mornigstar has a Buy rating and $62 fair value estimate for LVS stock.British American Tobacco PLC (NYSE: BTI)British American Tobacco is an international tobacco company that owns brands such as Lucky Strike, Newport and Camel and generates 45% of its revenue from the U.S. market.While cigarette volumes are likely in secular decline, Gorham says British American's accelerated volume declines in fiscal 2019 may be particularly troubling to investors. However, he says the company may be best-positioned to capitalize on the next generation of tobacco products, including its Vype and Vuse vaping brands an Glo heated tobacco brand. Gorham says British American's buyout of Reynolds American was a solid strategic move given its pricing power and the value of its assets.Morningstar has a Buy rating and $59 target for BTI stock.Anheuser Busch Inbev NV (NYSE: BUD)Anheuser Busch Inbev is the world's largest brewer and owner of brands such as Budweiser, Beck's and Corona.Gorham says the worst of the downturn may be yet to come for Anheuser Busch, but the company has plenty of liquidity to navigate the crisis. In the longer term, he says the company's near monopoly and cost advantages in developed markets make the stock a solid investment, and its potential for free cash flow generation isn't fully priced in at current levels. Gorham projects volumes will fall 20% in the first half of 2020 and only 7% in the second half of the year.Morningstar has a Buy rating and $96 fair value estimate for BUD stock.Altria Group Inc (NYSE: MO)Altria Group is one of the world's largest tobacco companies, but it's also one of the most diversified sin stocks. In addition to being the parent company of Philip Morris USA, Altria has a more than 10% ownership stake in Anheuser Busch, a 35% stake in vaping leader JUUL, and a 45% stake in cannabis stock Cronos.Gorham says COVID-19 has certainly disrupted Altria's business, but its underlying business trends in the first quarter appear to be solid. Cigarette shipment volume was up 6%, and management reiterated its guidance that industry-wide volume will drop between 4% and 6% this year.Morningstar has a Buy rating and $54 fair value estimate for MO stock.See Also: 7 Best-Performing Stocks Of 2020: Buy, Sell Or Hold?Constellation Brands, Inc. (NYSE: STZ)Constellation Brands is one of the world's largest producers of wine, spirits and imported beer and owns brands such as Arbor Mist, Black Velvet and SVEDKA. Constellation also recently upped its ownership stake in leading Canadian cannabis producer Canopy Growth Corp (NYSE: CGC) to nearly 40%.Analyst Nicholas Johnson says Constellation's beer business should help support numbers for now, and the sell-off in the stock has pushed it to "egregiously cheap" levels. In fact, given his bullish long-term outlook for Constellation, Johnson says it's his top stock pick in the pure-play beverage group.Morningstar has a Buy rating and $215 price target for STZ stock.Latest Ratings for CRON DateFirmActionFromTo May 2020StifelMaintainsHold Apr 2020Piper SandlerDowngradesOverweightNeutral Apr 2020B of A SecuritiesDowngradesBuyNeutral View More Analyst Ratings for CRON View the Latest Analyst RatingsSee more from Benzinga * Here's How Much Investing 0 In The 2018 Cronos Listing Would Be Worth Today * The Road To Recovery For Las Vegas Casino Stocks * Cannabis Stock Rally Puts Short Sellers In The Red For 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Tobacco Industry Outlook Smoking Hot on Pricing & RRP Focus
Fri, 15 May 2020 13:29:01 +0000
Tobacco Industry Outlook Smoking Hot on Pricing & RRP Focus

Top 5 Buys of Ray Dalio's Bridgewater in the 1st Quarter
Thu, 14 May 2020 23:21:13 +0000
The $165 billion hedge fund releases portfolio in a coronavirus-driven landscape Continue reading…

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.